AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24818542
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous ondansetron
Trial: 28956529
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil (1 mg/kg)
Trial: 24092829
Drug: High-phosphate diet
RxNorm normalized name: hydroxypropyl distarch phosphate, high amylose corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-phosphate diet (1800 mg/d) for 6 days
Trial: 19307106
Drug: AZI-IR 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZI-IR 500 mg
Trial: 17702589
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion starting in the operating theatre (Group OT)
Trial: 17702589
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion starting in the ICU (Group ICU)
Trial: 15080773
Drug: Ghrelin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin administration (both doses)
Trial: 11343562
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of milrinone (5 microg/kg/min)
Trial: 11343562
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without milrinone
Trial: 9806580
Drug: Beta2 glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta2 glycoprotein I IgM antibody and antinuclear antibody
Trial: 1096388
Drug: Once-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E1R1)
Trial: 1096388
Drug: Twice-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly regimen of rifampicin 1200 mg plus ethambutol 50 mg/kg body weight (E2R2)
Trial: 1096388
Drug: Initial inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial inpatient phase of rifampicin 600 mg and ethambutol 25 mg/kg daily for 12 weeks
Trial: 26562379
Drug: Wound Gel
RxNorm normalized name: Hylase Wound Gel
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound Gel
Trial: 26562379
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care plus Wound Gel (SOC + gel)
Trial: 21111078
Drug: Escalating dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose teriparatide (20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months)
Trial: 21111078
Drug: Constant dose
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant dose teriparatide (30 μg daily for 18 months)
Trial: 16273395
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication on
Trial: 16273395
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus (STN) stimulation with dopaminergic medication off
Trial: 16273395
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus (STN) stimulation off with low medication (usual dose)
Trial: 16273395
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus (STN) stimulation off with high medication (suprathreshold dose)
Trial: 16273395
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus (STN) stimulation on with low medication (usual dose)
Trial: 8088206
Drug: Portal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portal infusion with Mitomycin‐C (MMC) and 5‐Fluorouracil (5‐FU) starting immediately after operation
Trial: 26114379
Drug: Delayed-release (DR)
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release (DR) prednisone
Trial: 2840815
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg
Trial: 21980964
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lisinopril 10 mg and diclofenac sodium 100 mg
Trial: 17063170
Drug: P400 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P400 (400 mg phosphate)
Trial: 17063170
Drug: P800 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P800 (800 mg phosphate)
Trial: 17063170
Drug: P1200 (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1200 (1200 mg phosphate)
Trial: 12622767
Drug: Tegaserod (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod (6 mg b.d.)
Trial: 8368545
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of morphine
Trial: 6362490
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of epinephrine
Trial: 8368545
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.2 mg of morphine and 0.2 mg of epinephrine
Trial: 3545737
Drug: Amiloride HCl
RxNorm normalized name: amiloride HCl
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride HCl 5 mg + Hydrochlorothiazide 50 mg (AHCZ)
Trial: 29309832
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (300,000 IU oral doses at 8 weeks interval)
Trial: 18378381
Drug: Atorvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (5 mg/day)
Trial: 14522295
Drug: Dorzolamide-timolol combination
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol combination (Cosopt)
Trial: 10795763
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium butyrate (4 g/day) plus oral mesalazine (2.4 g/day)
Trial: 10795763
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine plus placebo
Trial: 1571381
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g of cefodizime
Trial: 1571381
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of cefodizime
Trial: 6488703
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of calcium (increased plasma calcium concentration by about 0.5 mmol/l)
Trial: 6488703
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of calcium infusion after 46 min
Trial: 6488703
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of sodium nitroprusside
Trial: 6488703
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of noradrenaline
Trial: 30284097
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure mask (CPAP), oxygen at 6 L/min, 5-15 cm H2O
Trial: 30284097
Drug: Simple oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple oxygen mask, oxygen at 6 L/min
Trial: 16084879
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of tibolone
Trial: 16084879
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of E2 plus 1 mg of norethisterone acetate (E2/NETA)
Trial: 16084879
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (CEE/MPA)
Trial: 16084879
Drug: No menopausal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No menopausal therapy (control)
Trial: 7473832
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (25 g daily)
Trial: 2258344
Drug: Pefloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (800 mg per day)
Trial: 2258344
Drug: Ampicillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (4 g per day) plus Gentamicin (240 mg per day im)
Trial: 31669049
Drug: 975 mg
RxNorm normalized name: aspirin 975 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 975 mg oral acetaminophen
Trial: 17968020
Drug: Ixabepilone plus
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone plus capecitabine (Ixabepilone 40 mg/m² IV on day 1 of a 21-day cycle plus capecitabine 2000 mg/m² orally on days 1-14 of a 21-day cycle)
Trial: 17968020
Drug: Capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine alone (2500 mg/m² on the same schedule)
Trial: 12121393
Drug: 50% tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% tea tree oil solution
Trial: 12121393
Drug: 25% tea
RxNorm normalized name: IODINE 2.5 g in 1 L TOPICAL SOLUTION [DariSoft .25% Teat Dip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% tea tree oil solution
Trial: 9893074
Drug: Voluntary unsupervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary unsupervised aerobic and step training (twice per week)
Trial: 2185822
Drug: Mifepristone 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 0 mg (placebo)
Trial: 20130470
Drug: Mifepristone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (all doses)
Trial: 391754
Drug: Pindolol, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol, 15 mg/day
Trial: 27977309
Drug: Coordinated inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordinated inhalation maneuver
Trial: 27977309
Drug: Uncoordinated inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncoordinated inhalation maneuver
Trial: 26124485
Drug: New ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New ointment containing several antioxidants
Trial: 26124485
Drug: New ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New ointment
Trial: 23728549
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid for 14 days
Trial: 21570071
Drug: Magnetic resonance-guided
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic resonance-guided focused ultrasound surgery (FUS) treatment of uterine fibroids
Trial: 11034245
Drug: Intravenous 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5-fluorouracil (5-FU) 450 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=74)
Trial: 11034245
Drug: Oral doxifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral doxifluridine 900 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=92)
Trial: 8769611
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg intravenous hyperimmune globulin (IVIG)
Trial: 1427133
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Timolol and Acetazolamide
Trial: 6427817
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg diazepam
Trial: 6427817
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg diazepam
Trial: 6427817
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg diazepam
Trial: 1750018
Drug: Nebulised amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised amiloride (1 mg in 3 ml saline) via System 22 nebuliser
Trial: 1750018
Drug: Nebulised amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised amiloride (1 mg in 3 ml saline) via Fisoneb nebuliser
Trial: 6311242
Drug: Pectin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin (12 g/d)
Trial: 6311242
Drug: Cellulose (15
RxNorm normalized name: methylcellulose (15 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose (15 g/d)
Trial: 6311242
Drug: Lignin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignin (12 g/d)
Trial: 29925775
Drug: Inulin supplement
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin supplement (10 g/day)
Trial: 22492372
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 3 to 59 mg kg(‐1) d(‐1)
Trial: 22492372
Drug: Current recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current recommended methionine intake of 28 mg kg(‐1) d(‐1)
Trial: 22492372
Drug: Infant formulas
RxNorm normalized name: infant formulas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formulas providing methionine intake of 49-80 mg kg(‐1) d(‐1)
Trial: 20307216
Drug: LUMIGAN (bimatoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUMIGAN (bimatoprost ophthalmic solution, 0.03%)
Trial: 20307216
Drug: TRAVATAN (travoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAVATAN (travoprost ophthalmic solution, 0.004%)
Trial: 18508828
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF), 400 microg once daily
Trial: 16996600
Drug: PDT followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDT followed by approximately 11 mg IVTA
Trial: 10442963
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Trial: 10442963
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Trial: 10442963
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.05 mg x kg(‐1))
Trial: 10442963
Drug: Thiopental (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.1 mg x kg(‐1))
Trial: 8685641
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g, i.v. every 8 h for 2 days)
Trial: 8685641
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further antibiotics
Trial: 8685641
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g i.v. at induction and 12 h postoperatively)
Trial: 1880233
Drug: Estazolam 2
RxNorm normalized name: estazolam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 2 mg
Trial: 549782
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (TA) 250-750 mg/die
Trial: 549782
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 50-150 mg/die
Trial: 549782
Drug: Tienilic acid
RxNorm normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tienilic acid (TA) 250-1000 mg/die in congestive heart failure patients
Trial: 17089219
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water treatment
Trial: 16429619
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg SL Apomorphine (APO)
Trial: 10998469
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg bezafibrate once daily
Trial: 24655345
Drug: Conventional language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional language therapy (CLT)
Trial: 22441361
Drug: S(+)‐ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine infusion for 60 hours
Trial: 15572276
Drug: Risperidone (4.2±1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4.2±1.7 mg/day)
Trial: 15572276
Drug: Haloperidol (8.0±3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (8.0±3.6 mg/day)
Trial: 15572276
Drug: Risperidone and
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone and Haloperidol (4.1±1.8 mg/day and 7.4±3.7 mg/day respectively) during the subsequent 9 weeks
Trial: 12540319
Drug: Nortriptyline (Pamelor)
RxNorm normalized name: nortriptyline Oral Capsule [Pamelor]
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (Pamelor) with weekly behavioral therapy
Trial: 9703790
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite in combination with physical therapy for 3 weeks
Trial: 9205761
Drug: Ebrotidine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 800 mg
Trial: 30779530
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (median of 22 hours daily for a median of 7 days)
Trial: 26181910
Drug: High-intensity rehabilitation
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity rehabilitation programme with cognitive behavioural therapy
Trial: 23642951
Drug: True Individualised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True Individualised Western Herbal Medicine (IWHM) tinctures
Trial: 23642951
Drug: Placebo Individualised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Individualised Western Herbal Medicine (IWHM) tinctures
Trial: 11315821
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (HOE 901) once daily (n = 259)
Trial: 11315821
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin once or twice daily (n = 259)
Trial: 11315821
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (HOE 901) once daily
Trial: 11315821
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin once or twice daily
Trial: 9220540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IA-2 beta and IA-2
Trial: 9220540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IA-2 beta and GAD65
Trial: 9220540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IA-2 and GAD65
Trial: 3400843
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine alone
Trial: 3400843
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine with adrenaline 1:1000
Trial: 31383449
Drug: Anapanasati meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anapanasati meditation (daily for 6 months)
Trial: 26226227
Drug: Insulin (2-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (2-mg bovine insulin/kg body mass)
Trial: 26226227
Drug: Oleate (OL)
RxNorm normalized name: oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleate (OL) (300 μg/kg)
Trial: 26226227
Drug: Octanoate (OCT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octanoate (OCT) (300 μg/kg)
Trial: 26226227
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Oleate
Trial: 26226227
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Octanoate
Trial: 26226227
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline solution alone)
Trial: 21807930
Drug: HMB/ARG/LYS (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB/ARG/LYS (n = 40) with vitamin D status <30 ng 25OH-vitD(3)/mL